Display options
Cite
Broos K, Van der Jeught K, Puttemans J, et al. Particle-mediated Intravenous Delivery of Antigen mRNA Results in Strong Antigen-specific T-cell Responses Despite the Induction of Type I Interferon. Mol Ther Nucleic Acids. 2016;5(6):e326doi: 10.1038/mtna.2016.38.
Broos, K., Van der Jeught, K., Puttemans, J., Goyvaerts, C., Heirman, C., Dewitte, H., Verbeke, R., Lentacker, I., Thielemans, K., & Breckpot, K. (2016). Particle-mediated Intravenous Delivery of Antigen mRNA Results in Strong Antigen-specific T-cell Responses Despite the Induction of Type I Interferon. Molecular therapy. Nucleic acids, 5(6), e326. https://doi.org/10.1038/mtna.2016.38
Broos, Katrijn, et al. "Particle-mediated Intravenous Delivery of Antigen mRNA Results in Strong Antigen-specific T-cell Responses Despite the Induction of Type I Interferon." Molecular therapy. Nucleic acids vol. 5,6 (2016): e326. doi: https://doi.org/10.1038/mtna.2016.38
Broos K, Van der Jeught K, Puttemans J, Goyvaerts C, Heirman C, Dewitte H, Verbeke R, Lentacker I, Thielemans K, Breckpot K. Particle-mediated Intravenous Delivery of Antigen mRNA Results in Strong Antigen-specific T-cell Responses Despite the Induction of Type I Interferon. Mol Ther Nucleic Acids. 2016 Jun 21;5(6):e326. doi: 10.1038/mtna.2016.38. PMID: 27327138; PMCID: PMC5022130.
Copy Download .nbib Format: NLM
Share it on

Mol Ther Nucleic Acids. 2016 Jun 21;5(6):e326. doi: 10.1038/mtna.2016.38.

Particle-mediated Intravenous Delivery of Antigen mRNA Results in Strong Antigen-specific T-cell Responses Despite the Induction of Type I Interferon.

Molecular therapy. Nucleic acids

Katrijn Broos, Kevin Van der Jeught, Janik Puttemans, Cleo Goyvaerts, Carlo Heirman, Heleen Dewitte, Rein Verbeke, Ine Lentacker, Kris Thielemans, Karine Breckpot

Affiliations

  1. Laboratory of Molecular and Cellular Therapy, Department of Biomedical Sciences, Vrije Universiteit Brussel, Brussels, Belgium.
  2. Laboratory for General Biochemistry and Physical Pharmacy, Faculty of Pharmacy, Ghent University, Ghent, Belgium.

PMID: 27327138 PMCID: PMC5022130 DOI: 10.1038/mtna.2016.38

Abstract

Cancer vaccines based on mRNA are extensively studied. The fragile nature of mRNA has instigated research into carriers that can protect it from ribonucleases and as such enable its systemic use. However, carrier-mediated delivery of mRNA has been linked to production of type I interferon (IFN) that was reported to compromise the effectiveness of mRNA vaccines. In this study, we evaluated a cationic lipid for encapsulation of mRNA. The nanometer-sized, negatively charged lipid mRNA particles (LMPs) efficiently transfected dendritic cells and macrophages in vitro. Furthermore, i.v. delivery of LMPs resulted in rapid expression of the mRNA-encoded protein in spleen and liver, predominantly in CD11c(+) cells and to a minor extent in CD11b(+) cells. Intravenous immunization of mice with LMPs containing ovalbumin, human papilloma virus E7, and tyrosinase-related protein-2 mRNA, either combined or separately, elicited strong antigen-specific T-cell responses. We further showed the production of type I IFNs upon i.v. LMP delivery. Although this decreased the expression of the mRNA-encoded protein, it supported the induction of antigen-specific T-cell responses. These data question the current notion that type I IFNs hamper particle-mediated mRNA vaccines.

References

  1. J Immunol. 1999 Jan 15;162(2):989-94 - PubMed
  2. Blood. 2005 May 15;105(10):3824-32 - PubMed
  3. Expert Rev Vaccines. 2015 Feb;14(2):235-51 - PubMed
  4. Cancer Immunol Immunother. 2013 Dec;62(12):1769-80 - PubMed
  5. Mol Ther. 2013 Jan;21(1):251-9 - PubMed
  6. Nat Biotechnol. 2011 Feb;29(2):154-7 - PubMed
  7. Handb Exp Pharmacol. 2008;(183):221-35 - PubMed
  8. Biomaterials. 2003 Apr;24(8):1409-18 - PubMed
  9. J Biol Chem. 2004 Mar 26;279(13):12542-50 - PubMed
  10. Virology. 2005 Nov 25;342(2):177-89 - PubMed
  11. Semin Immunol. 2013 Apr;25(2):152-9 - PubMed
  12. J Cell Sci. 2009 Jun 1;122(Pt 11):1713-21 - PubMed
  13. J Immunol. 2002 Oct 15;169(8):4279-87 - PubMed
  14. Gene Ther. 1997 Sep;4(9):950-60 - PubMed
  15. Eur J Immunol. 1993 Jul;23(7):1719-22 - PubMed
  16. Nat Nanotechnol. 2008 Mar;3(3):145-50 - PubMed
  17. Mol Pharm. 2008 Jul-Aug;5(4):487-95 - PubMed
  18. J Biol Chem. 2003 Oct 10;278(41):39858-65 - PubMed
  19. Eur J Immunol. 2001 Jul;31(7):2026-34 - PubMed
  20. J Immunol. 2002 May 1;168(9):4391-8 - PubMed
  21. J Immunother. 2009 Jun;32(5):498-507 - PubMed
  22. J Gene Med. 2005 Apr;7(4):452-65 - PubMed
  23. Cancer Res. 2010 Nov 15;70(22):9031-40 - PubMed
  24. J Mol Med (Berl). 2006 Sep;84(9):774-84 - PubMed
  25. Biochem Soc Trans. 2007 Feb;35(Pt 1):68-71 - PubMed
  26. J Mater Sci Mater Med. 2009 Sep;20(9):1881-91 - PubMed
  27. Oncotarget. 2015 Jan 30;6(3):1359-81 - PubMed
  28. Langmuir. 2009 Mar 3;25(5):3013-21 - PubMed
  29. Science. 2006 Nov 10;314(5801):994-7 - PubMed
  30. Eur J Immunol. 2005 May;35(5):1557-66 - PubMed
  31. J Clin Invest. 2011 May;121(5):1782-96 - PubMed
  32. Cancer Res. 2015 Feb 1;75(3):497-507 - PubMed
  33. Mol Ther. 2008 Nov;16(11):1833-40 - PubMed
  34. Nat Immunol. 2000 Jul;1(1):70-6 - PubMed
  35. J Exp Med. 2005 May 2;201(9):1435-46 - PubMed
  36. Nanoscale. 2014 Jul 21;6(14):7715-29 - PubMed
  37. Hum Vaccin Immunother. 2013 Feb;9(2):265-74 - PubMed
  38. Cancer Res. 2012 Apr 1;72(7):1661-71 - PubMed
  39. Oncotarget. 2014 Oct 30;5(20):10100-13 - PubMed
  40. Sci Rep. 2014 Jun 04;4:5128 - PubMed
  41. J Immunol. 2002 Jul 1;169(1):531-9 - PubMed
  42. J Control Release. 2007 Nov 20;123(3):184-94 - PubMed
  43. Oncotarget. 2014 Feb 15;5(3):704-15 - PubMed
  44. J Immunother. 2011 Jan;34(1):1-15 - PubMed
  45. Nanomedicine. 2011 Aug;7(4):445-53 - PubMed
  46. Cell Host Microbe. 2012 Jun 14;11(6):631-42 - PubMed
  47. Gene Ther. 2011 Jul;18(7):702-8 - PubMed
  48. Clin Cancer Res. 2011 May 1;17(9):2619-27 - PubMed
  49. Endocr Metab Immune Disord Drug Targets. 2009 Dec;9(4):328-43 - PubMed
  50. J Control Release. 2014 Dec 10;195:138-46 - PubMed
  51. Hum Gene Ther. 1999 Nov 1;10(16):2719-24 - PubMed
  52. PLoS One. 2014 Jul 24;9(7):e101644 - PubMed
  53. J Virol. 2010 Jun;84(11):5627-36 - PubMed
  54. J Exp Med. 2011 Sep 26;208(10):2005-16 - PubMed
  55. Expert Rev Vaccines. 2015 Feb;14(2):161-76 - PubMed
  56. Clin Dev Immunol. 2012;2012:153863 - PubMed
  57. Eur J Nucl Med Mol Imaging. 2008 May;35(5):999-1007 - PubMed
  58. J Control Release. 2010 Aug 3;145(3):182-95 - PubMed
  59. Immunity. 2005 Aug;23(2):165-75 - PubMed
  60. Biochim Biophys Acta. 1998 Feb 16;1390(2):119-33 - PubMed
  61. Blood. 2011 Sep 15;118(11):3028-38 - PubMed
  62. J Virol. 2013 Oct;87(20):11304-8 - PubMed
  63. Immunity. 1998 May;8(5):591-9 - PubMed
  64. Gene Ther. 2012 Dec;19(12):1133-40 - PubMed
  65. Immunotherapy. 2011 May;3(5):605-7 - PubMed
  66. Drug Discov Today. 2016 Jan;21(1):11-25 - PubMed
  67. Nature. 2003 Mar 6;422(6927):37-44 - PubMed

Publication Types